IL1B抗体—艾普蒂

+ +

•  

   

     Western blot analysis of extracts from LOVO cells, using LMTK2 antibody P42041.    

  
  

•  

   

     Immunofluorescence analysis of HepG2 cells, using LMTK2 antibody P42041.    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded human brain tissue using LMTK2 antibody P42041.    

  
  

The interleukin-1 beta (IL1B) antibody is a biological tool designed to target IL-1β, a pro-inflammatory cytokine central to innate immune responses. Encoded by the IL1B gene, IL-1β is produced primarily by macrophages, monocytes, and dendritic cells as an inactive precursor (pro-IL-1β) that requires cleavage by caspase-1 via inflammasome activation to become biologically active. Mature IL-1β binds to the IL-1 receptor (IL-1R), triggering downstream signaling pathways (e.g., NF-κB, MAPK) that drive inflammation, fever, and tissue repair. Dysregulated IL-1β production is implicated in autoimmune diseases (e.g., rheumatoid arthritis), autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes), and chronic inflammatory conditions (e.g., atherosclerosis, diabetes).

IL1B antibodies, including monoclonal antibodies like canakinumab, neutralize IL-1β activity by blocking its interaction with IL-1R. These antibodies are used both as research tools to study IL-1β pathways in disease models and as therapeutics to suppress excessive inflammation. Clinically, IL1B-targeting biologics have shown efficacy in reducing disease severity in conditions such as gout, systemic juvenile idiopathic arthritis, and cytokine release syndrome. Development of IL1B antibodies emphasizes specificity to avoid cross-reactivity with related cytokines (e.g., IL-1α) and optimization for pharmacokinetic stability. Challenges include balancing potent neutralization with minimizing immunosuppressive side effects. Ongoing research explores their potential in cancer immunotherapy and neurodegenerative diseases linked to chronic inflammation.